Drug use evaluation of tamoxifen focusing on off-label use in a managed care population in Israel

Journal of Managed Care Pharmacy

Volumn 16, Issue 5, 2010, Pages 355-359

  Kahan, Natan R ^a,b   Waitman, Dan Andrei ^a   Blackman, Shimon ^a   Vardy, Daniel A ^a,c  

^a Leumit Health Care System   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; TAMOXIFEN CITRATE;

ANOVULATION; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL TRIAL; DATA BASE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; FEMALE INFERTILITY; HEALTH CARE ORGANIZATION; HUMAN; INFORMATION; INTERNATIONAL CLASSIFICATION OF DISEASES; ISRAEL; MEDICAL RECORD REVIEW; MEDICAL SPECIALIST; MEDLINE; OBSERVATION; OFF LABEL DRUG USE; OVARY CANCER; PALLIATIVE THERAPY; PATIENT CARE; PHYSICIAN; POPULATION; RETROSPECTIVE STUDY; TREATMENT INDICATION;

EID: 77953302137     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.5.355     Document Type: Article

References (11)

1. Ansani N, Sirio C, Smitherman T, et al. Designing a strategy to promote safe, innovative, off-label use of medications. Am J Med Qual. 2006;21(4):255-61. (Pubitemid 44035784)
2. Curtiss, FR, Fairman KA. Contradictory actions on off-label use of prescription drugs? The FDA and CMS versus the U.S. Justice Department. J Manag Care Pharm. 2009;15(2):161-65. Available at: http://www.amcp.org/data/jmcp/161- 165.pdf.
3. Gillick MR. Controlling off-label medication use. Ann Intern Med. 2009;150(5):344-47. Available at: http://www.annals.org/content/150/5/344.full. pdf+html. Accessed May 25, 2010.
4. Chernichovsky D. Not "socialized medicine" - an Israeli view of health care reform. N Engl J Med. 2009;361(21):e46.
5. The Israel Drug Registry. Available at: http://www.health.gov.il/units/ pharmacy/trufot/PerutTrufa.asp?Reg-Number=106 08 26581 00&safa=. Accessed May 25, 2010.
6. Williams C. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2001;(1):CD001034. Abstract available at: http://www.ncbi.nlm.nih.gov/ pubmed/11279703. Accessed May 25, 2010.
7. Boostanfar R, Jain JK, Mishell DR Jr, Paulson RJ. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril. 2001;75(5):1024-26. (Pubitemid 32401686)
8. Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005;20(6):1511-15. Available at: http://humrep.oxfordjournals.org/cgi/reprint/ 20/6/1511. Accessed May 25, 2010. (Pubitemid 40852240)
9. Beck JI, Boothroyd C, Proctor M, Farquhar C, Hughes E. Oral antioestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev. 2005;(1):CD002249. Abstract available at: http://www.ncbi.nlm.nih.gov/pubmed/15674894. Accessed May 25, 2010.
10. Nolvadex (tamoxifen citrate) tablets. AstraZeneca Pharmaceuticals. September 27, 2005. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2006/017970s054lbl.pdf. Accessed May 25, 2010.
11. MICROMEDEX 1.0 (Healthcare Series) DrugPoint Summary: tamoxifen citrate. Thomson Reuters.